Macular Degeneration Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration), By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD), By Treatment Type (Drug, Devices, Surgery), By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other), By Region, By Competition 2020-2030F

Market Overview

The Global Macular Degeneration Treatment Market will grow from USD 14.19 Billion in 2024 to USD 22.90 Billion by 2030 at a 8.30% CAGR. Macular degeneration treatments encompass a range of pharmacological interventions, primarily anti-vascular endothelial growth factor (anti-VEGF) agents, along with other supportive therapies designed to manage age-related macular degeneration (AMD), a progressive ophthalmic condition leading to central vision loss. The market's growth is fundamentally driven by the escalating global aging population, which directly increases AMD prevalence, alongside advancements in diagnostic capabilities and growing patient awareness regarding early detection.

According to the Global Burden of Disease Study Collaborators, in a meta-analysis published in June 2025, the number of individuals with vision impairment due to AMD globally rose from 3.64 million in 1990 to 8.06 million in 2021, highlighting a significant and expanding patient demographic. The substantial economic burden associated with long-term treatment regimens, particularly the recurring intravitreal administration of anti-VEGF agents, presents a significant challenge that could impede market expansion by limiting patient access and straining healthcare budgets across various regions.

Key Market Drivers

The global macular degeneration treatment market is significantly propelled by the increasing worldwide prevalence of age-related macular degeneration and continuous advancements in therapeutic modalities and drug development. The rising incidence of AMD creates an expanding patient pool demanding effective interventions. For instance, according to Eye Health Central, in 2025, approximately 200 million people worldwide are living with some form of age-related macular degeneration, underscoring the vast and growing clinical need that drives market demand. Concurrently, the landscape of treatment is evolving rapidly through significant innovations in drug development. These advancements include novel agents and non-invasive therapies designed to address previously unmet needs, particularly in dry AMD. As reported by Duke Department of Ophthalmology in "FDA Approves New Treatment for Dry AMD with the Help of Duke Researchers", in November 2024, the FDA approved a new light delivery system, photobiomodulation, for intermediate dry age-related macular degeneration, marking the first non-invasive approved treatment for vision loss in dry AMD patients and exemplifying progress in expanding therapeutic options.

These primary drivers collectively foster an environment ripe for sustained market expansion. Strategic investments by major pharmaceutical entities further highlight the perceived growth potential within this therapeutic area. For example, according to PharmaBoardroom, in its July 2025 article "Top Ophthalmology Trends to Watch in 2025", Merck acquired EyeBio for USD 1.3 billion, securing access to Restoret, a promising therapy for age-related macular degeneration and diabetic macular edema, demonstrating substantial corporate confidence in vision care innovation. This robust capital influx supports continued research and development for long-acting anti-VEGF agents, gene therapies, and treatments for geographic atrophy, critical for addressing long-term disease management and reducing patient treatment burden.

Download Free Sample Report

Key Market Challenges

The substantial economic burden associated with long-term treatment regimens, particularly the recurring intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents, directly hampers the growth of the global macular degeneration treatment market. This financial strain presents a significant barrier, limiting patient access to necessary therapies and placing considerable pressure on healthcare budgets across various regions. The chronic nature of age-related macular degeneration (AMD) necessitates ongoing treatment, often involving frequent injections, which accumulates substantial costs over time for individuals and health systems.

This economic challenge demonstrably restricts market expansion by reducing the overall pool of treated patients. According to a study presented at the American Academy of Ophthalmology 2024 annual meeting, patients with an annual income below $50,000 exhibited a 43% lower rate of eye examinations and a 77% lower utilization rate of advanced diagnostic procedures like fundus photography or macular optical coherence tomography, compared to those with incomes exceeding $100,000. Such disparities underscore how treatment costs disproportionately affect patient engagement with critical ophthalmic services, leading to delayed or incomplete care. Consequently, this financial impediment constrains the market's potential for growth, irrespective of the increasing prevalence of AMD.

Key Market Trends

The development of complement system inhibitors for dry age-related macular degeneration (AMD) represents a significant growth trend, addressing a substantial unmet medical need. Geographic atrophy, an advanced form of dry AMD, previously lacked approved disease-modifying therapies. These novel inhibitors target specific components of the complement cascade, an immune pathway implicated in dry AMD's pathogenesis and progression. Such targeted treatments offer the potential to slow disease progression and preserve vision. Apellis Pharmaceuticals, a key innovator, reported $611.9 million in U.S. net product revenue for SYFOVRE, a complement C3 inhibitor for geographic atrophy, for the full year 2024, demonstrating rapid market adoption and commercial impact. This trend signifies a shift towards mitigating underlying molecular mechanisms.

Innovation in ocular drug delivery systems is another critical trend, aiming to alleviate treatment burden and improve patient adherence in macular degeneration management. Traditional intravitreal injections require frequent clinic visits, posing challenges for both patients and healthcare systems. New delivery platforms, including sustained-release implants, extend dosing intervals and offer less invasive administration. Roche’s Susvimo, a refillable ocular implant for wet AMD, was reintroduced in July 2024 following design modifications to enhance safety and performance, with the FDA expanding its approval to include diabetic macular edema in 2025. These advancements are crucial for enhancing the patient experience and ensuring consistent therapeutic effects, broadening treatment accessibility.

Segmental Insights

The Wet Age-related Macular Degeneration segment is experiencing rapid growth within the global macular degeneration treatment market, establishing itself as the fastest-growing area. This acceleration is primarily driven by the escalating prevalence of age-related macular degeneration due to an aging global demographic. Furthermore, significant advancements in therapeutic approaches, particularly the widespread adoption of effective anti-vascular endothelial growth factor (anti-VEGF) agents, have revolutionized disease management by offering improved visual outcomes and slowing disease progression. Enhanced diagnostic capabilities also contribute by enabling earlier and more accurate detection, facilitating timely treatment intervention. Additionally, a robust pipeline of innovative treatments and supportive regulatory oversight from bodies like the FDA and EMA foster trust and market expansion.

Regional Insights

North America leads the global macular degeneration treatment market due to its highly developed healthcare infrastructure and substantial investment in research and development, fostering continuous innovation in therapies. The region benefits from favorable reimbursement frameworks, including coverage from Medicare and private payers, which support the adoption of advanced and often costly treatments. Furthermore, the strong presence of major pharmaceutical companies actively engaged in developing novel solutions, coupled with high awareness levels and widespread access to sophisticated diagnostic tools, contributes significantly to market dominance. The proactive role of regulatory bodies such as the U.S. Food and Drug Administration in approving new treatments also accelerates market growth and patient access to essential medications.

Recent Developments

• In November 2025, Apellis Pharmaceuticals presented new five-year post-hoc analysis data from the GALE extension study for SYFOVRE (pegcetacoplan injection). This breakthrough research confirmed that continuous treatment with SYFOVRE significantly delayed the progression of geographic atrophy (GA) secondary to age-related macular degeneration by approximately 1.5 years. The data reinforced the long-term efficacy of both monthly and every-other-month dosing regimens in reducing GA lesion growth, offering a crucial insight into managing this advanced form of dry AMD. The safety profile remained consistent with prior reports throughout the five-year period.

• In October 2025, Eli Lilly expanded its presence in the global macular degeneration treatment market through the acquisition of Adverum Biotechnologies for $261.7 million. This strategic collaboration brought Adverum's Ixo-vec, an investigational single-dose intravitreal gene therapy, into Eli Lilly's pipeline. Ixo-vec is currently in development for the treatment of wet age-related macular degeneration (AMD), aiming to reduce the burden of frequent eye injections for patients. The acquisition underscores a growing interest in gene therapy approaches to provide long-term solutions for ophthalmic diseases.

• In November 2024, LumiThera received FDA de novo market authorization for its Valeda Light Delivery System, a significant new product launch in the global macular degeneration treatment market. This non-invasive photobiomodulation (PBM) device is intended for the treatment of early and intermediate dry age-related macular degeneration (AMD). Clinical studies demonstrated that this light therapy system could slow the progression of vision loss and, in some cases, lead to improved vision by stimulating mitochondrial cells in the eye. This approval represented a novel treatment option for a patient population with limited alternatives.

• In July 2024, Roche's Genentech unit announced the reintroduction of its Susvimo implant for patients with wet age-related macular degeneration (AMD) in the United States. Susvimo had been voluntarily withdrawn from the market in 2022 due to manufacturing defects. Following component-level updates to the implant and its refill needle, the U.S. Food and Drug Administration granted a new approval, clearing the path for its relaunch. This refillable eye implant is designed to deliver a continuous supply of ranibizumab, a common anti-VEGF drug, potentially reducing the frequency of injections required for patients with wet AMD.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• PanOptica Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Aerie Pharmaceutical Inc.
• REGENXBIO Inc.
• Bayer AG
• Lineage Cell Therapeutics Inc

Report Scope:

In this report, the Global Macular Degeneration Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Macular Degeneration Treatment Market, By Type:

o   Dry Age-related Macular Degeneration

o   Wet Age-related Macular Degeneration

• Macular Degeneration Treatment Market, By Stage of Disease:

o   Early-stage AMD

o   Intermediate AMD

o   Late-stage AMD

• Macular Degeneration Treatment Market, By Treatment Type:

o   Drug

o   Devices

o   Surgery

• Macular Degeneration Treatment Market, By Sales Channel:

o   Ambulatory Surgical Centers

o   Hospitals

o   Other

• Macular Degeneration Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Macular Degeneration Treatment Market.

Available Customizations:

Global Macular Degeneration Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Macular Degeneration Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]